Quentis Therapeutics
PRIVATE
STATUS
Accelerator/Inc
LATEST DEAL TYPE
9
INVESTORS
Description
Developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company inhibitor is designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
- 430 East 29th Street
- Suite 1005
- New York, NY 10016
- United States
+1 (646) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Quentis Therapeutics’s full profile, request a free trial.
Quentis Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Accelerator/Incubator | 01-Sep-2018 | 000.00 | Completed | Product Development | ||
| 3. Early Stage VC (Series A) | 27-Feb-2018 | 000.00 | 000.00 | 000.00 | Completed | Product Development |
| 2. Seed Round | 22-Nov-2017 | $2M | $5M | 0000 | Completed | Startup |
| 1. Seed Round | 09-Jun-2016 | $3M | $3M | 000 | Completed | Startup |
Quentis Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Seed | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Quentis Therapeutics Competitors (39)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Corvidia | Venture Capital-Backed | Waltham, MA | 0 | 000.00 | 00000000000 | 000.00 |
| 0000 000000 | Formerly VC-backed | Santa Monica, CA | 000 | 00000 | 000000&0 | 00000 |
| 00000000 | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 | |
| 00000000 | Formerly VC-backed | Munich, Germany | 000.00 | 000000&0 | 000.00 |
Quentis Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| JLABS | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | ||
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| New York Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Polaris Partners | Venture Capital | Minority | 000 0000 | 000000 0 |
Quentis Therapeutics Executive Team (5)
Quentis Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Amy Schulman JD | Polaris Partners | Board Member | 000 0000 | |
| Carlo Rizzuto Ph.D | Versant Venture Management | Board Member | 000 0000 | |
| Charles Kunsch Ph.D | AbbVie Ventures | Board Observer | 000 0000 | |
| Laurie Glimcher MD | Self | Scientific Co-Founder & Chairman, Scientific Advisory Board | 000 0000 | |
| Mark Murcko Ph.D | Self | Board Member | 000 0000 |